Loading...

Futura Medical plc

FUM.L•LSE
Healthcare
Biotechnology
£11.85
£3.98(50.57%)

Futura Medical plc (FUM.L) Stock Overview

Explore Futura Medical plc’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 69.2/100

Key Financials

Market Cap34.6M
P/E Ratio25.69
EPS (TTM)$-0.01
ROE0.15%
Fundamental Analysis

AI Price Forecasts

1 Week$9.50
1 Month$9.08
3 Months$19.80
1 Year Target$23.62

FUM.L Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Futura Medical plc (FUM.L) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 73.21, suggesting the stock is in an overbought condition. Our forecasting models predict significant price movements, with a 12-month target of $23.62.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of 25.69 and a market capitalization of 34.6M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

73.21RSI (14)
-0.05MACD
19.95ADX
Stats data is not available for FUM.LStats details for FUM.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for FUM.LAnalyst Recommendations details for FUM.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

Futura Medical plc, a pharmaceutical company, develops pharmaceutical and healthcare products for the consumer healthcare markets focusing on sexual health and pain relief management. Its lead product is MED3000, a topical gel for the treatment of erectile dysfunction. The company also develops pain relief products, including TPR100, a topical diclofenac pain relief gel; CBD100, a topical cannabidiol formulation; and TIB200, a topical ibuprofen pain relief gel. The company was incorporated in 2001 and is headquartered in Guildford, the United Kingdom.

CEO

James Henry Barder

Employees

14

Headquarters

Surrey Technology Centre, Guildford

Founded

2003

Frequently Asked Questions

;